

Developer of mRNA-molecules for therapeutic and prophylactic vaccines. The company has developed RNAdjuvant that enhances the immune response to a large number of different vaccines, including protein and peptide-based vaccines, without toxic effects. Among its major competitors, CureVac is ranked in 10th place for NPS while Boehringer Ingelheim is 1st, and Sarepta Therapeutics is 2nd.